Work

Recommended and Prevalent Use of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter-2 Inhibitors in a National Population-Based Sample

Year: 2023

Type: article

Abstract: Background:The 2022 consensus report from the American Diabetes Association and European Association for the Study of Diabetes recommended using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among persons with type 2 diabetes (T2D) who have established or are at high risk for atherosclerotic cardiovascular disease (ASCVD), and using sodiumglucose cotransporter-2 inhibitors (SGLT2is) among those with T2D who have established ASCVD, chronic kidney disease, or heart failure or are at high risk for ASCVD (level A evidence) (1). Objective:To estimate, using nationally representative data, the number and percentage of persons with T2D who would meet the recommended criteria and were using these medications in the United States.

Source: Annals of Internal Medicine

DOI: 10.7326/m22-3051

Authors: Shichao Tang, Hui Shao, Mohammed K. Ali, Ping Zhang

Institutions: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Emory University

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Diabetes and Digestive and Kidney Diseases